Clinical Trial Update: VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 clinical trial evaluates atezolizumab in combination with chemotherapy for pediatric relapsed or refractory solid tumors, including rhabdom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhabdomyosarcoma

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Solid Tumor, Rhabdomyosarcoma | Phase 1, Phase 2 | Status: RECRUITING